MORPHOGENESIS, INC.
IFx-Hu2.1, a cream-based plasmid DNA immunotherapeutic encoding bacterial antigen Emm55 to activate immune responses against cervical cancer and HPV-related dysplasia
- Sector
- Biotech
- Total capital
- $400K
- Federal grants
- $400K
- 1 award · 2021
- Rank in peer group#338 of 502
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 9 pending · first 2017
- Rank in peer group#13 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · A low-cost topical immunotherapy formulation suitable for treating cervical cancer in low and middle income countries and low-resource settings in the U.S.$400K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#13 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Michael C. LawmanResearcherDirectorLinked by 6 patents
- Michael John ShamblottResearcherExecutive OfficerLinked by $400K in grants as PI
- Dan DearbornExecutive OfficerNamed in SEC Form D filings
- Daniel DearbornExecutive OfficerNamed in SEC Form D filings
- David John BergmannDirectorNamed in SEC Form D filings
- David John LawmanDirectorNamed in SEC Form D filings
Show all 15 people
- George C. NgDirectorNamed in SEC Form D filings
- Grahame John CookDirectorNamed in SEC Form D filings
- James BiancoExecutive Officer, DirectorNamed in SEC Form D filings
- James John McNultyDirectorNamed in SEC Form D filings
- Joseph John ErricoDirectorNamed in SEC Form D filings
- Kiran C. PatelDirectorNamed in SEC Form D filings
- Patricia Dianne LawmanExecutive Officer, DirectorNamed in SEC Form D filings
- Peter John StaatsDirectorNamed in SEC Form D filings
- Scott John SlaytonExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 15- PendingExosome Delivery Of Cancer TherapeuticsUSPTOApplication 18055724
- PendingModified Mrna For Multicell TransformationUSPTOApplication 16869642
- GrantedDna Vector And Transformed Tumor Cell VaccinesUSPTOUS 10,751,400
Show all 15 patent records
- Exosome Delivery Of Cancer TherapeuticsJun 15, 2023 · Application 18055724Pending
- Modified Mrna For Multicell TransformationOct 8, 2020 · Application 16869642Pending
- Dna Vector And Transformed Tumor Cell VaccinesAug 25, 2020 · US 10,751,400Granted
- Multi-indication Mrna Cancer ImmunotherapyJun 16, 2020 · US 10,682,401Granted
- Dna Vector And Transformed Tumor Cell VaccinesAug 27, 2019 · US 10,391,158Granted
- Dna Vector And Transformed Tumor Cell VaccinesDec 12, 2017 · US 9,839,680Granted
- Multi-indication Mrna Cancer ImmunotherapyMay 2, 2017 · US 9,636,388Granted
- Dna Vector And Transformed Tumor Cell VaccinesJan 31, 2017 · US 9,555,088Granted
- Exosome Delivery Of Cancer TherapeuticsApplication 63279218Pending
- Multi-indication Mrna Cancer ImmunotherapyApplication PCTUS2016033235Pending
- Dna Vector And Transformed Tumor Cell VaccinesApplication PCTUS2015018688Pending
- Dna Vector And Transformed Tumor Cell VaccinesApplication PCTUS2018064811Pending
- Tumor Cell VaccinesApplication PCTUS2008067199Pending
- Multi-indication Mrna Cancer ImmunotherapyApplication PCTUS2018030142Pending
- Modified Mrna For Multicell TransformationApplication PCTUS2021031204Pending
Related companies, and why
- Magnet BiomedicineSimilar federal contract value in Biotech · null in contracts
- GENESEARCH, INC.Similar federal contract value in Biotech · null in contracts
- RayTheraSimilar federal contract value in Biotech · null in contracts
- MathNimbus IncSimilar federal contract value in Biotech · null in contracts
- INHIPROT, LLCSimilar federal contract value in Biotech · null in contracts
- SENSEION, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .